By Louis Navellier of
1. Valeant Pharmaceuticals InternationalValeant Pharmaceuticals International ( VRX) develops drugs for a variety of illnesses and ailments, including epilepsy, Parkinson's disease, migraines and acne. But Valeant has changed a lot. It recently completed a merger with Biovail, the largest pharmaceutical company in Canada. Even though this was marketed as a merger, it was structured as a buyout as if Biovail is buying the old Valeant. Valeant stockholders will receive, for each share of VRX stock held prior to the merger, 1.7809 shares of Biovail (after the merger, the combined company changes its name to Valeant). In addition, the company will issue a one-time dividend of $16.77 per share to every old Valeant shareholder of record as of Sept. 27. During the past several months, Valeant Pharmaceuticals and Biovail rallied in tandem as their merger was being finalized. Since September, VRX has gained 11%. VRX will announce earnings for the third quarter sometime in early November. Analysts are expecting earnings of $0.81 per share, an increase of nearly 20% from the previous quarter and sales of $297.1 million, a 25% year-over-year increase. I predict this stock will surge as we near its report, so continue to buy VRX while it remains under $28 per share.
2. Acme PacketAcme Packet ( APKT) is a communications equipment company that witnessed a surge in institutional interest in the third quarter as institutional investors increased their holdings of the company's stock by nearly 25%. The reason institutional investors, including banks, financial advisories and mutual funds, have become so interested in APKT is because of earnings. Analysts are predicting earnings of $0.19 per share on sales of $54.9 million. Compared with last year's results, the data represents a 111% earnings increase and a 51% sales increase. In all likelihood, actual results will come in even higher as analysts aggressively have been revising these estimates higher in the past several months. APKT itself even raised its yearly forecast in its most-recent quarterly financial report.
3. NetflixNetflix ( NFLX) has had an outstanding past several weeks, gaining 22% since September. This performance has caught the attention of analysts, and we've seen one downgrade on the stock because of this big move. While we will likely see some profit taking after a run like this, I still like the stock.
4. Spreadtrum CommunicationsSpreadtrum Communications ( SPRD) was on quite a clip in September, ending the month 21% higher despite a wave of profit-taking that sunk the stock slightly in the final week of the month. The chip company designs and markets baseband communications chips for mobile phones in China, one of the fastest-growing wireless markets in the world. The company also recently announced the world's first triple SIM in single chip solution, a technology that allows three GSM SIM cards -- chips used to run mobile devices -- to operate simultaneously in one mobile phone. The rapid growth of Spreadtrum's business will be evidenced in the company's forthcoming third-quarter earnings report to be released on Nov. 15. The company forecasts sales of between $88 million and $96 million, on par with current analysts' estimates of $92 million. Sales are predicted to rise 140% year-over-year along with earnings, which should grow from $0.01 per share in the third quarter of 2009 to $0.33 per share this year, a more than 3,000% jump. In the past three months, analysts have revised earnings estimates +18% higher. To me, this indicates a probable earnings surprise. Buy this stock under $16.